The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting its successful pivot toward specialized pharmaceutical growth, Teva Pharmaceuticals reported strong quarterly results driven by the record performance of UZEDY. According to reports, net sales for the schizophrenia treatment reached $77 million in Q2 2026, marking a 43% year-on-year increase. The drug is currently positioned as the fastest-growing long-acting injectable treatment in the U.S. market.
Following this momentum, Teva has raised its 2026 revenue outlook for UZEDY to a range of $270 million to $290 million. This upward revision highlights continued growth in key product lines, benefiting both Teva and its partner Medincell. The guidance update underscores management's confidence in the product's ability to capture further market share throughout the remainder of the fiscal year.
Market data shows TEVA shares closed at $31.67 as of July 28, 2026, after trading between a session low of $31.02 and a high of $31.88. Investors should monitor broader market sentiment following upcoming economic catalysts, including German Consumer Confidence and UK Retail Sales data scheduled for release on July 24.